These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8493423)

  • 21. Oncology data management in the UK--BODMA's view. British Oncology Data Managers Association.
    Riley D; Ward L; Young T
    Br J Cancer; 1994 Sep; 70(3):391-4. PubMed ID: 8080719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Behind closed doors: the data monitoring board in randomized clinical trials.
    Wittes J
    Stat Med; 1993 Mar; 12(5-6):419-24. PubMed ID: 8493420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Standardization, more funds on horizon for clinical trials.
    McNeil C
    J Natl Cancer Inst; 2005 Apr; 97(8):555-7. PubMed ID: 15840874
    [No Abstract]   [Full Text] [Related]  

  • 26. SOP 09: Statistical design and analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
    [No Abstract]   [Full Text] [Related]  

  • 27. The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
    Anderson JR; Krailo M
    Am J Bioeth; 2011 Mar; 11(3):18-9. PubMed ID: 21400379
    [No Abstract]   [Full Text] [Related]  

  • 28. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
    Ellenberg SS; George SL
    Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
    Lachin JM
    Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interim analyses, stopping rules and data monitoring in clinical trials in Europe.
    Buyse M
    Stat Med; 1993 Mar; 12(5-6):509-20. PubMed ID: 8493429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Site visit monitoring program of the clinical cooperative groups: results of the first 3 years.
    Mauer JK; Hoth DF; Macfarlane DK; Hammershaimb LD; Wittes RE
    Cancer Treat Rep; 1985 Oct; 69(10):1177-87. PubMed ID: 4042096
    [No Abstract]   [Full Text] [Related]  

  • 32. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations.
    Hurria A; Dale W; Mooney M; Rowland JH; Ballman KV; Cohen HJ; Muss HB; Schilsky RL; Ferrell B; Extermann M; Schmader KE; Mohile SG;
    J Clin Oncol; 2014 Aug; 32(24):2587-94. PubMed ID: 25071116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Institutional review boards: a crisis in confidence.
    Levine RJ
    Ann Intern Med; 2001 Jan; 134(2):161-3. PubMed ID: 11177321
    [No Abstract]   [Full Text] [Related]  

  • 34. Data monitoring committees: the moral case for maximum feasible independence.
    Walters L
    Stat Med; 1993 Mar; 12(5-6):575-80; discussion 581-2. PubMed ID: 8493433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical trials in cancer.
    Green JA
    Br J Cancer; 2011 May; 104(10):1521-2. PubMed ID: 21559023
    [No Abstract]   [Full Text] [Related]  

  • 36. The statistician and the data monitoring committee.
    D'Agostino RB
    Stat Med; 2004 May; 23(10):1501-2. PubMed ID: 15122726
    [No Abstract]   [Full Text] [Related]  

  • 37. [Interim analyses].
    Kramar A; Paoletti X
    Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Barriers to clinical trial enrollment: are state mandates the solution?
    Hillner BE
    J Natl Cancer Inst; 2004 Jul; 96(14):1048-9. PubMed ID: 15265958
    [No Abstract]   [Full Text] [Related]  

  • 39. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.
    Abrams JS; Mooney MM; Zwiebel JA; Korn EL; Friedman SH; Finnigan SR; Schettino PR; Denicoff AM; Kruhm MG; Montello M; Misra RR; Ansher SS; DiPiazza KJ; Souhan EM; Wickerham DL; Giantonio BJ; O'Donnell RT; Sullivan DM; Soto NI; Fleming GF; Prindiville SA; Petryshyn RA; Hautala JA; Grad O; Zuckerman BL; Meyer RM; Yao JC; Baker LA; Buckner JC; Hortobagyi GN; Doroshow JH
    J Natl Cancer Inst; 2013 Jul; 105(13):954-9. PubMed ID: 23776198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.